Taiwan’s Newborn Test for Rare Sugar‑Metabolism Disorders

In August 2015, Taiwan began testing every newborn for a group of rare enzyme problems called mucopolysaccharidoses (MPS). The goal was to find the disease early and start treatment before serious damage occurs. Researchers later reviewed how many babies were caught, when they were diagnosed, and what happened afterward. The study looked at all the results from the national program. It measured how many infants tested positive, when doctors confirmed the disease, and what treatments were started. The data showed that babies who were identified early had better chances of staying healthy and avoiding severe complications.Because the test is done for all newborns, doctors can spot MPS even before symptoms appear. Early diagnosis means families can plan for therapy and care right away, which often improves quality of life. The research also highlighted how the program has changed over ten years. It compared earlier data with recent results, showing improvements in test accuracy and faster follow‑up care. The program has become a model for other countries that want to add rare disease screening. Overall, Taiwan’s experience demonstrates that nationwide newborn testing for MPS can save lives and reduce long‑term health problems. It also shows that early treatment is key to better outcomes for these rare conditions.